Prescribe TRUVADA for pre-exposure prophylaxis only as part of a comprehensive prevention strategy that includes other prevention measures, such as safer sex practices, because TRUVADA is not always effective in preventing the acquisition of HIV-1 infection.
- Counsel uninfected individuals about safer sex practices that include consistent and correct use of condoms, limiting the number of sexual partners, knowledge of their HIV-1 status and that of their partner(s), and regular testing for other sexually transmitted infections that can facilitate HIV-1 transmission (such as syphilis and gonorrhea)
- Inform uninfected individuals about and support their efforts in reducing sexual risk behavior
Prescribe TRUVADA to reduce the risk of acquiring HIV-1 infection only in individuals confirmed to be HIV-1 negative. HIV-1 resistance substitutions may emerge in individuals with undetected HIV-1 infection who are taking only TRUVADA, because TRUVADA alone does not constitute a complete treatment regimen for HIV-1 treatment; therefore, care should be taken to minimize drug exposure in HIV-1 infected individuals.
- Evaluate for signs or symptoms of acute HIV-1 infection prior to prescribing and while taking TRUVADA
- You must confirm a negative HIV-1 test immediately prior to prescribing TRUVADA for a PrEP indication. If clinical symptoms consistent with acute viral infection are present and recent (<1 month) exposures are suspected, delay starting TRUVADA for at least 1 month and reconfirm HIV-1 negative status or use a test approved by the FDA as an aid in the diagnosis of HIV-1 infection, including acute or primary HIV-1 infection
- Screen for HIV-1 infection at least once every 3 months while taking TRUVADA for a PrEP indication. If symptoms consistent with acute HIV-1 infection develop following a potential exposure event, PrEP should be discontinued until negative infection status is confirmed using a test approved by the FDA as an aid in the diagnosis of HIV-1, including acute or primary HIV-1 infection
Counsel uninfected individuals to strictly adhere to the recommended TRUVADA daily dosing schedule. The effectiveness of TRUVADA in reducing the risk of acquiring HIV-1 infection is strongly correlated with adherence and measurable drug levels.
It’s important to remember that TRUVADA for a PrEP indication is contraindicated in individuals with unknown or positive HIV-1 status. TRUVADA should only be used in HIV-1 infected patients in combination with other antiretroviral agents.
Access tools that can help you manage and counsel individuals on the correct and safe use of TRUVADA for a PrEP indication.
MaterialsDownload important materials for healthcare providers and uninfected individuals about TRUVADA for a PrEP indication
Post-Training Review QuestionsAssess your knowledge of TRUVADA for a PrEP indication by answering
a series of review questions